45,359 results match your criteria Hodgkin Disease


Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor T-cell therapy.

Expert Rev Hematol 2019 Feb 22. Epub 2019 Feb 22.

a Division of Medical Oncology, Department of Internal Medicine , University of Washington School of Medicine , Seattle , WA , USA.

Introduction: Chimeric antigen receptor (CAR) T cell immunotherapy has demonstrated remarkable anti-tumor activity in B-cell malignancies and is under investigation in other hematologic malignancies and solid tumors. While highly efficacious, post-infusion T cell activity often results in massive cytokine release precipitating cytokine release syndrome (CRS), the signature toxicity of CAR T cells. This toxicity is characterized by systemic immune activation resulting in fever, hypotension, respiratory insufficiency and capillary leak. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2019.1585238DOI Listing
February 2019

A good response of refractory mantel cell lymphoma to haploidentical CAR T cell therapy after failure of autologous CAR T cell therapy.

J Immunother Cancer 2019 Feb 21;7(1):51. Epub 2019 Feb 21.

Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.

Background: The aggressive form of Mantle cell non-hodgkin B cell lymphoma (MCL) has a dismal prognosis. Dual targeting BTK and BCL2 with ibrutinib and venetoclax has improved outcomes in MCL patients who were predicted not to respond to conventional therapy, but it is unlikely to be curative. Chimeric antigen receptor-modified T (CAR T) cells exhibit very effective function in elimination of relapsed/refractory B-cell lymphoid malignancies, we investigated their use in a patient with relapsed MCL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-019-0529-9DOI Listing
February 2019

Lymphoma diagnostics: getting more from less.

Br J Haematol 2019 Feb 19. Epub 2019 Feb 19.

Department of Pathology, University of Utah and ARUP Laboratories, Salt Lake City, UT, USA.

In the modern era, clinicians and pathologists increasingly make challenging diagnoses in patients with suspected lymphoma using minimal amounts of diagnostic material. The increase in utilization of minimally invasive procedures, such as fine needle aspiration or needle core biopsies, lead to challenges in our ability to make accurate histopathological assessments of disease, including the integration of new diagnostic and prognostic testing, with smaller amounts of material. The trend towards minimally invasive diagnostics is also often in conflicting interest with researchers seeking to study tissue specimens to better understand the biology and genetics of these diseases to move the field forward. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15788DOI Listing
February 2019

Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma.

Blood Cancer J 2019 Feb 19;9(3):22. Epub 2019 Feb 19.

Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA.

Treatment with programmed death-1 (PD-1) blocking antibodies results in high overall response rates in refractory and relapsed classical Hodgkin lymphoma (cHL) patients, indicating that PD-1/PD-1 ligand interactions are integral to progression of this disease. Given the genetically driven increased PD-L1/2 expression in HL, we hypothesized that reverse signaling through PD-1 ligands may be a potential mechanism contributing to the growth and survival of Hodgkin Reed-Sternberg (HRS) cells in cHL. Our data show that engagement of PD-L1 using an agonistic monoclonal antibody increases cell survival and proliferation and reduces apoptosis in HL cell lines. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-019-0185-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6381098PMC
February 2019

New directions in treating peripheral T-cell lymphomas (ptcl): leveraging epigenetic modifiers alone and in combination.

Expert Rev Hematol 2019 Feb 20. Epub 2019 Feb 20.

a Center for Lymphoid Malignancies, Division of Hematology and Oncology, Department of Medicine , Columbia University Medical Center, College of Physicians and Surgeons , New York , N.Y. , USA.

Introduction: The peripheral T-cell lymphomas (PTCL) are a rare and heterogeneous group of non-Hodgkin lymphomas originating from mature T- and NK-cells. They are aggressive diseases often resistant to chemotherapy. Areas Covered: The methodology of this review involves a literature search of data published on PubMed, abstracts from international conferences, and our own research. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2019.1583102DOI Listing
February 2019

CD30 expression in a case of intravascular large B-cell lymphoma, cutaneous variant.

J Cutan Pathol 2019 Feb 18. Epub 2019 Feb 18.

Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti, Università degli Studi di Milano, Milan, Italy.

Intravascular large B-cell lymphoma (IVLBCL) is one of the rarest B-cell non Hodgkin lymphomas (NHL), with an aggressive clinical behavior and a poor prognosis; in fact, its treatment is still an unmet clinical need, with a 3-year overall survival (OS) rate of 60-81%, and a central nervous system relapse rate of 25%. It usually presents as a widespread disease at diagnosis with multi-organ involvement. Previously considered as a diffuse large B-cell lymphoma variant, it now represents a different extranodal large B-cell lymphoma entity in the last WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cup.13446DOI Listing
February 2019

MRD Detection in B-Cell Non-Hodgkin Lymphomas Using Ig Gene Rearrangements and Chromosomal Translocations as Targets for Real-Time Quantitative PCR.

Methods Mol Biol 2019 ;1956:199-228

Second Medical Department, University Hospital Schleswig-Holstein, Kiel, Germany.

Minimal residual disease (MRD) diagnostics is of high clinical relevance in patients with indolent B-cell non-Hodgkin lymphomas (B-NHL) and serves as a surrogate parameter to evaluate treatment effectiveness and long-term prognosis. MRD diagnostics performed by real-time quantitative PCR (RQ-PCR) is still the gold standard and currently the most sensitive and the most broadly applied method in follicular lymphoma (FL) and mantle cell lymphoma (MCL). Alternatively, droplet digital PCR (ddPCR) can be used for MRD monitoring in multiple myeloma, mantle cell lymphoma, and follicular lymphoma with comparable sensitivity, accuracy, and reproducibility. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-4939-9151-8_9DOI Listing
January 2019

Flow Cytometry for Non-Hodgkin and Hodgkin Lymphomas.

Methods Mol Biol 2019 ;1956:35-60

Department of Laboratory Medicine, University of Washington Medical Center, Seattle, WA, USA.

Multiparametric flow cytometry is a powerful diagnostic tool that permits rapid assessment of cellular antigen expression to quickly provide immunophenotypic information suitable for disease classification. This chapter describes a general approach for the identification of abnormal lymphoid populations by flow cytometry, including B, T, NK, and Hodgkin lymphoma cells suitable for the clinical and research environment. Knowledge of the common patterns of antigen expression of normal lymphoid cells is critical to permit identification of abnormal populations at disease presentation and for minimal residual disease assessment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-4939-9151-8_2DOI Listing
January 2019

Intravascular large B-cell lymphoma: The Great Imitator.

Autops Case Rep 2018 Oct-Dec;8(4):e2018055. Epub 2018 Nov 30.

University of Vermont Medical Center, Department of Pathology and Laboratory Medicine. Burlington, Vermont, USA.

Intravascular large B-cell lymphoma (IVLBCL) is a rare subtype of diffuse large B-cell lymphoma with an estimated incidence of less than one per million. Unlike other hematopoietic malignancies, lymphadenopathy and hepatosplenomegaly are uncommon, and patients typically present with nonspecific symptoms. IVLBCL presents a diagnostic challenge and patients are usually diagnosed late in the disease course, if at all, and the prognosis is poor. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4322/acr.2018.055DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360824PMC
November 2018

The Comparison Between Microwave and Autoclave as Antigen Retrieval Methods for Immunohistochemical Detection of CD15 and CD30 in Hodgkin's Lymphoma.

Iran J Pathol 2018 25;13(4):390-396. Epub 2018 Sep 25.

Pathology Laboratory, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.

Background And Objective: Hodgkin's lymphoma is a potentially curable hematologic malignancy with difficulty in its diagnosis especially in atypical cases even in expert hands. Today, immunohistochemistry plays a significant role in the diagnosis of it especially applying the anti-CD15 and anti-CD30 antibodies. The negativity of CD15 can be reduced by antigen retrieval for methods. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358563PMC
September 2018

Analysis of circulating tumor DNA by targeted ultra-deep sequencing across various non-Hodgkin lymphoma subtypes.

Leuk Lymphoma 2019 Feb 18:1-10. Epub 2019 Feb 18.

g Department of Medicine , Samsung Medical Center, Sungkyunkwan University School of Medicine , Seoul , Korea.

Although targeted deep sequencing of cell-free DNA (cfDNA) was recently used to investigate tumor somatic mutations in particular subtypes of non-Hodgkin lymphomas (NHLs), the immense genetic heterogeneity across subtypes poses a hurdle to design a universal gene panel applicable for diverse subtypes of NHLs. We designed a panel targeting 66 genes associated with NHLs and performed targeted deep sequencing to analyze plasma cfDNA from patients with various subtypes of NHLs. Genetic profiling in plasma cfDNA using the method resulted in 88. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1573998DOI Listing
February 2019
1 Read

[Clinicopathological features and possible prognostic factors in parotid lymphomas].

Beijing Da Xue Xue Bao Yi Xue Ban 2019 Feb;51(1):35-42

Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology & National Clinical Research Center for Oral Diseases & National Engineering Laboratory for Digital and Material Technology of Stomatology & Beijing Key Laboratory of Digital Stomatology, Beijing 100081, China.

Objective: To investigate the clinicopathological features and prognostic factors in lymphoma of parotid origin.

Methods: Clinicopathological data of the patients with parotid lymphoma who were initially diagnosed in Peking University Hospital of Stomatology from 2006 to 2016 were collected and analyzed retrospectively. The patients were followed-up for 5 to 149 months with a median period of 45 months, and the factors influencing the prognosis were evaluated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.19723/j.issn.1671-167X.2019.01.007DOI Listing
February 2019

Prevalence of deaths in a cohort of girls and women with cryopreserved ovarian tissue.

Acta Obstet Gynecol Scand 2019 Feb 15. Epub 2019 Feb 15.

The Fertility Clinic, section 4071, University Hospital of Copenhagen Rigshospitalet, Copenhagen, Denmark.

Introduction: Ovarian tissue cryopreservation (OTC) is increasingly offered to women in need of fertility preservation. However, little is known about the risk of these women dying before they use the preserved material.

Material And Methods: From 1999 to 2016, 927 girls and women underwent OTC in our center, prior to receiving gonadotoxic treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/aogs.13576DOI Listing
February 2019
1 Read

The Roles of FDG PET-CT in Predicting the Adverse Effects of Chimeric Antigen Receptor T Cell Therapy Treating Patients with Non-Hodgkin Lymphoma.

Biol Blood Marrow Transplant 2019 Feb 12. Epub 2019 Feb 12.

PET-CT Center, the First Affiliated Hospital, Zhejiang University. Electronic address:

Background: CD19-targeting chimeric antigen receptor (CAR) T cell therapy has shown great efficacy in patients with relapsed/refractory non-Hodgkin lymphoma (NHL), but has been associated with serious adverse effects such as cytokine release syndrome (CRS). It has been speculated that NHL baseline disease burden might affect clinical outcome and CRS, but such assumption has not been explored in detail. Metabolic tumor volume (MTV) and total lesion glycolysis (TLG), as measured by FDG PET-CT, are quantitative indicators of baseline tumor burden. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.02.008DOI Listing
February 2019
1 Read

Development of Hepatic Steatosis After Chemotherapy for Non-Hodgkin Lymphoma.

Hepatol Commun 2019 Feb 28;3(2):220-226. Epub 2018 Dec 28.

Liver and Energy Metabolism Unit, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases National Institutes of Health Bethesda MD.

Nonalcoholic fatty liver disease is the most common liver disorder in the developed world. Although typically reflecting caloric overload, it can also be secondary to drug toxicity. We aimed to describe the incidence and risk factors for steatosis during chemotherapy for non-Hodgkin lymphoma (NHL). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep4.1304DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357828PMC
February 2019
1 Read

Overall and Site-Specific Cancer Mortality in Patients on Dialysis and after Kidney Transplant.

J Am Soc Nephrol 2019 Feb 14. Epub 2019 Feb 14.

School of Public Health, University of Sydney, Sydney, Australia.

Patients with ESRD have a substantially increased cancer risk, but few studies have examined the patterns of cancer mortality along a patient's journey from dialysis to transplantation.

Methods: We identified all Australian patients on dialysis and patients with transplants from 1980 to 2014 from the Australia and New Zealand Dialysis and Transplant Registry. Using standardized mortality ratios (SMRs), we compared cancer mortality among patients on dialysis and patients with transplants versus the general population (overall and by age, sex, year, and site); we also performed a subgroup analysis excluding patients with preexisting cancers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1681/ASN.2018090906DOI Listing
February 2019
2 Reads
9.343 Impact Factor

Rare disease knowledge enrichment through a data-driven approach.

BMC Med Inform Decis Mak 2019 Feb 14;19(1):32. Epub 2019 Feb 14.

Department of Health Sciences Research, Mayo Clinic, 205 3rd Ave SW, Rochester, MN, 55905, USA.

Background: Existing resources to assist the diagnosis of rare diseases are usually curated from the literature that can be limited for clinical use. It often takes substantial effort before the suspicion of a rare disease is even raised to utilize those resources. The primary goal of this study was to apply a data-driven approach to enrich existing rare disease resources by mining phenotype-disease associations from electronic medical record (EMR). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12911-019-0752-9DOI Listing
February 2019

Patterns of Failure and Survival Outcomes After Total Lymphoid Irradiation and High-Dose Chemotherapy With Autologous Stem Cell Transplantation for Relapsed or Refractory Classical Hodgkin Lymphoma.

Int J Radiat Oncol Biol Phys 2019 Feb 11. Epub 2019 Feb 11.

Department of Radiation Oncology, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL. Electronic address:

Purpose: The patterns of failure and long-term outcomes of patients with relapsed or refractory classical Hodgkin lymphoma (cHL) treated with total lymphoid irradiation (TLI) and high-dose chemotherapy (HDCT) followed by autologous stem cell transplantation (aSCT) is reported.

Methods And Materials: Patients with biopsy-proven primary refractory/relapsed cHL who received salvage chemotherapy and accelerated hyperfractionated TLI prior to HDCT and aSCT were included. Patterns of failure were delineated after fusing pretransplant planning computed tomography (CT) scan to the scan reporting the first failure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2019.02.007DOI Listing
February 2019

A Rare Case of Bilateral Proptosis.

Eur J Case Rep Intern Med 2018 28;5(11):000966. Epub 2018 Nov 28.

Medicine IV Department, Hospital Prof. Doutor Fernando Fonseca, Amadora, Portugal.

A 65-year-old man presented with a 2-year history of severe bilateral proptosis, palpable lymphadenopathy and moderate hepatosplenomegaly. A blood test was positive for hepatitis C infection. CT showed palpebral infiltrative lesions with regional progression through the temporal and masticatory spaces to the pharynx and hypopharynx causing almost complete airway obstruction. Read More

View Article

Download full-text PDF

Source
https://www.ejcrim.com/index.php/EJCRIM/article/view/966
Publisher Site
http://dx.doi.org/10.12890/2018_000966DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346810PMC
November 2018
4 Reads

Biology and therapy of primary mediastinal B-cell lymphoma: current status and future directions.

Br J Haematol 2019 Feb 10. Epub 2019 Feb 10.

Blood Cancer Research Group, Mater Research, University of Queensland, Translational Research Institute, Brisbane, QLD, Australia.

Primary mediastinal B-cell lymphoma (PMBCL) is a distinct disease closely related to classical nodular sclerosing Hodgkin lymphoma. Conventional diagnostic paradigms utilising clinical, morphological and immunophenotypical features can be challenging due to overlapping features with other B-cell lymphomas. Reliable diagnostic and prognostic biomarkers that are applicable to the conventional diagnostic laboratory are largely lacking. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15778DOI Listing
February 2019
1 Read

Efficacy of nivolumab as checkpoint inhibitor drug on survival rate of patients with relapsed/refractory classical Hodgkin lymphoma: a meta-analysis of prospective clinical study.

Clin Transl Oncol 2019 Feb 9. Epub 2019 Feb 9.

Mother and Child Welfare Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.

Aims: The primary standard treatment for classic Hodgkin's lymphoma (cHL) is chemotherapy and radiation therapy. However, some patients get relapsed, or their diseases become resistant. PD1 blocking antibodies have been used to increase the response of treatment in solid tumors, and led to potentially stable responses that are acceptable. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12094-018-02032-4
Publisher Site
http://dx.doi.org/10.1007/s12094-018-02032-4DOI Listing
February 2019
7 Reads

Probability of carcinogenesis due to involved field and involved site radiation therapy techniques for supra- and infradiaphragmatic Hodgkin's disease.

Phys Med 2019 Jan 3;57:100-106. Epub 2019 Jan 3.

Department of Medical Physics, Faculty of Medicine, University of Crete, P.O. Box 2208, Heraklion 71003, Crete, Greece.

Purpose: To estimate the second cancer risk associated with Hodgkin Lymphoma (HL) radiotherapy at supradiaphragmatic or infradiaphragmatic region, using the involved field (IFRT) and the involved site radiotherapy (ISRT).

Materials And Methods: IFRT and ISRT treatment plans were created for twenty HL patients. Three dimensional plans (3DRT) were employed for all patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejmp.2018.12.036DOI Listing
January 2019
1 Read

Pediatric non-Hodgkin lymphoma: Characteristics, stratification, and treatment at a single institute in Thailand.

Pediatr Int 2019 Jan;61(1):49-57

Department of Pediatrics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

Background: In the modern era of chemotherapy, the outcome of pediatric non-Hodgkin lymphoma (NHL) continues to improve internationally. Limited data such as information on epidemiology and survival, however, are available in Asian countries.

Methods: Children (≤15 years old) diagnosed with histologically proven NHL from 1998 to 2014 were retrospectively analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ped.13739DOI Listing
January 2019
1 Read

Relapsing Long-Lasting Garcin Syndrome Revealing Skull Base Diffuse B Cell Lymphoma: The Diagnosis through the "Hartel's Route".

J Neurol Surg B Skull Base 2019 Feb 8;80(1):105-108. Epub 2018 Jun 8.

Department of NESMOS (Neurosciences Mental Health and Sensory Organs), School of Medicine and Psychology, "Sant'Andrea" Hospital, "Sapienza" University of Rome, Rome, Italy.

The Garcin syndrome is a rare condition characterized by multiple unilateral cranial nerve palsy, without neither long-tract involvement nor intracranial hypertension. Non-Hodgkin lymphoma is a systemic malignant disease that localizes in a minority of cases in the central nervous system. We report a case of Garcin syndrome that revealed a diffuse large B cell lymphoma (DLBCL) located in the skull base and in the right kidney. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/s-0038-1657794DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6365233PMC
February 2019
1 Read

Burkitt-like lymphoma with 11q aberration: A germinal center derived lymphoma genetically unrelated to Burkitt lymphoma.

Haematologica 2019 Feb 7. Epub 2019 Feb 7.

Institut Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain;

Burkitt-like lymphoma with 11q aberration is characterized by pathological features and gene expression profile resembling Burkitt lymphoma but lack MYC rearrangement and carries an 11q-arm aberration with proximal gains and telomeric losses. Whether these lymphomas are a distinct category or a particular variant of other recognized entities is controversial. To improve the understanding of Burkitt-like lymphoma with 11q aberration we have performed an analysis of copy number alterations and targeted sequencing of a large panel of B-cell lymphoma related genes in 11 cases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.207928DOI Listing
February 2019
1 Read

Factors affecting lymphocyte collection efficiency for the manufacture of chimeric antigen receptor T cells in adults with B-cell malignancies.

Transfusion 2019 Feb 6. Epub 2019 Feb 6.

Fred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, Washington.

Background: The clinical and procedural parameters that affect the optimal collection of lymphocytes for the production of chimeric antigen receptor (CAR) T cells remain undefined but are increasingly important, as commercial products are now available. We evaluated determinants of low lymphocyte collection efficiency (CE) and the rate of successful CAR T-cell manufacture in middle-aged and older adults with advanced B-cell malignancies.

Study Designs And Methods: Mononuclear cell collections using two apheresis platforms (COBE Spectra and Spectra Optia, Terumo BCT) from patients participating in a CD19-directed CAR T-cell therapy trial were reviewed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/trf.15178DOI Listing
February 2019
7 Reads

Lymphomas associated with chronic hepatitis C virus infection: A prospective multicenter cohort study from the Rete Ematologica Lombarda (REL) clinical network.

Hematol Oncol 2019 Feb 6. Epub 2019 Feb 6.

Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.

Chronic hepatitis C virus (HCV) infection is related with an increased risk of non-Hodgkin lymphomas (NHL). In indolent subtypes, regression of NHL was reported after HCV eradication with antiviral therapy (AT). In 2008 in Lombardy, a region of Northern Italy, the "Rete Ematologica Lombarda" (REL, Hematology Network of Lombardy-Lymphoma Workgroup) started a prospective multicenter observational cohort study on NHL associated with HCV infection, named "Registro Lombardo dei Linfomi HCV-positivi" ("Lombardy Registry of HCV-associated non-Hodgkin lymphomas"). Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/hon.2575
Publisher Site
http://dx.doi.org/10.1002/hon.2575DOI Listing
February 2019
6 Reads

Relapse Risk and Loss of Lifetime After Modern Combined Modality Treatment of Young Patients With Hodgkin Lymphoma: A Nordic Lymphoma Epidemiology Group Study.

J Clin Oncol 2019 Feb 6:JCO1801652. Epub 2019 Feb 6.

3 Karolinska Institutet, Solna, Sweden.

Purpose: Estimates of short- and long-term survival for young patients with classic Hodgkin lymphoma (cHL) are of considerable interest. We investigated cHL prognosis in the era of contemporary treatment at different milestones during the follow-up.

Patients And Methods: On the basis of a Nordic cohort of 2,582 patients diagnosed at ages 18 to 49 years between 2000 and 2013, 5-year relapse risks and 5-year restricted losses in expectation of lifetime were estimated for all patients and for patients who achieved event-free survival (EFS) for 12 (EFS12), 24 (EFS24), 36 (EFS36) or 60 (EFS60) months. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.18.01652DOI Listing
February 2019
1 Read

A PET Radiomics Model to Predict Refractory Mediastinal Hodgkin Lymphoma.

Sci Rep 2019 Feb 4;9(1):1322. Epub 2019 Feb 4.

Department of Radiation Oncology, Division of Radiation Oncology, MD Anderson Cancer Center, Houston, TX, USA.

First-order radiomic features, such as metabolic tumor volume (MTV) and total lesion glycolysis (TLG), are associated with disease progression in early-stage classical Hodgkin lymphoma (HL). We hypothesized that a model incorporating first- and second-order radiomic features would more accurately predict outcome than MTV or TLG alone. We assessed whether radiomic features extracted from baseline PET scans predicted relapsed or refractory disease status in a cohort of 251 patients with stage I-II HL who were managed at a tertiary cancer center. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41598-018-37197-z
Publisher Site
http://dx.doi.org/10.1038/s41598-018-37197-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361903PMC
February 2019
2 Reads
5.078 Impact Factor

Genetics of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL).

Aesthet Surg J 2019 Jan;39(Supplement_1):S14-S20

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.

Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a newly included provisional entity in the 2016 revision of the World Health Organization classification, is a distinct form of CD30-positive T-cell non-Hodgkin lymphoma that arises in association with a breast implant after reconstructive or cosmetic surgery. In addition to its characteristic clinical presentation, recent studies using next-generation sequencing have revealed that BIA-ALCL has a unique pattern of genetic alterations. BIA-ALCL is consistently negative for ALCL-related gene rearrangements involving ALK, DUSP22, and TP63. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/asj/sjy311DOI Listing
January 2019
2 Reads

Long-term survivors of childhood, adolescent and young adult non-Hodgkin lymphoma.

Br J Haematol 2019 Feb 3. Epub 2019 Feb 3.

Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN, USA.

Progress in overall survival rates for childhood non-Hodgkin lymphoma (NHL) can be largely attributed to effective development and conduct of a number of international treatment studies. Knowledge gained from these studies has shifted the treatment paradigm from a "one-size fits all" strategy to a histologically dependent approach. More specifically, many now adhere to a risk-stratified approach, prescribing cumulative doses and intensities of chemotherapeutic exposures based upon the aggressiveness of disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15775DOI Listing
February 2019
1 Read

A Rare Case of Primary Uterine Non-Hodgkins's Lymphoma with Involvement of Right Ovary: Staging with 18F FDG PET/CT and Iodinated Contrast CT.

Indian J Nucl Med 2019 Jan-Mar;34(1):60-61

Department of Biomedicine and Prevention University of Rome "Tor Vergata", Italy.

Primary uterine non-Hodgkin's lymphomas are extremely rare, and consequently, imaging findings of this disease have rarely been reported in the literature. We present fluorine-18-fluorodeoxyglucose ([F] FDG) positron emission tomography/computerized tomography (CT) and iodinated contrast CT findings in a young patient with primary uterine non-Hodgkin's B-cell lymphoma with right ovary involvement. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/ijnm.IJNM_116_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6352632PMC
February 2019
1 Read

Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial.

Lancet Haematol 2019 Feb;6(2):e100-e109

The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Background: Therapeutic approaches for B-cell malignancies continue to evolve, especially with regard to combination approaches. We assessed the safety and efficacy of the triplet ublituximab, umbralisib, and ibrutinib in patients with advanced B-cell malignancies.

Methods: We did an open-label, phase 1 study with dose-escalation and dose-expansion phases, at five centres in the USA. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S23523026183021
Publisher Site
http://dx.doi.org/10.1016/S2352-3026(18)30216-3DOI Listing
February 2019
3 Reads

Limitation in Patient-Reported Function Is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation.

Biol Blood Marrow Transplant 2019 Jan 30. Epub 2019 Jan 30.

Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California. Electronic address:

Although the use of geriatric assessment (GA) in the allogeneic hematopoietic cell transplantation (HCT) setting has been widely reported, few studies have evaluated the impact of patient-reported function on autologous HCT (autoHCT) outcomes. In this study, GA, including the administration of Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) quality of life tool, was performed in 184 patients age ≥50 years (median age, 61 years; range, 50 to 75 years) before autoHCT. Associations among GA findings, quality of life metrics, and post-transplantation outcomes were evaluated using Cox regression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.01.028DOI Listing
January 2019
1 Read

Clinical intensity-modulated proton therapy for Hodgkin lymphoma: which patients benefit the most?

Pract Radiat Oncol 2019 Jan 29. Epub 2019 Jan 29.

Clinical Trial Service Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK; Oxford Cancer Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Purpose: Radiotherapy (RT) improves control of Hodgkin lymphoma (HL), but patients undergoing RT are at risk of late effects, including cardiovascular disease and second cancers, due to radiation dose to organs at risk (OAR). Proton therapy (PT) can reduce OAR dose compared to conventional photon RT. However, access to PT is currently limited so referral must be appropriately selective. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S18798500193000
Publisher Site
http://dx.doi.org/10.1016/j.prro.2019.01.006DOI Listing
January 2019
9 Reads

Identification of human endogenous retrovirus transcripts in Hodgkin Lymphoma cells.

Mol Biol Rep 2019 Feb 1. Epub 2019 Feb 1.

University Clinic and Outpatient Clinic for Pediatrics I, Martin Luther University Halle-Wittenberg, Ernst-Grube-Str. 40, 06120, Halle, Germany.

During the last decades, the prognosis for patients with Hodgkin Lymphoma (HL) has been steadily improved. Nevertheless, new and less toxic therapy strategies have to be developed especially for patients with advanced disease. The activation of human endogenous retroviruses (HERV) is suspected to occur in HL and therefore, HERV might represent interesting target structures. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11033-019-04640-x
Publisher Site
http://dx.doi.org/10.1007/s11033-019-04640-xDOI Listing
February 2019
3 Reads

Mature (non-anaplastic, non-cutaneous) T-/NK-cell lymphomas in children, adolescents and young adults: state of the science.

Br J Haematol 2019 Feb 1. Epub 2019 Feb 1.

Department of Pediatrics, New York Medical College, Valhalla, NY, USA.

Mature (non-anaplastic) T-cell and natural killer (NK)-lymphomas rarely occur in children or adolescents. Due to the low incidence and heterogeneity, information regarding the aetiology, physiopathology and genetics of paediatric mature (non-anaplastic) T/NK-cell lymphoma is lacking. In addition, standard treatments have not yet been established. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15767DOI Listing
February 2019
1 Read

Novel targeted therapeutic agents for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma.

Br J Haematol 2019 Jan 30. Epub 2019 Jan 30.

Department of Paediatric and Adolescent Oncology, Gustave Roussy, Villejuif, France.

Non-Hodgkin lymphomas (NHLs) are a heterogeneous group of malignancies. Most NHLs in children, adolescent and young adult patients are aggressive lymphomas that are generally treated with multi-agent chemotherapy or immunochemotherapy regimens. While overall survival is high, the treatment can lead to a high rate of acute and long-term toxicity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15783DOI Listing
January 2019
2 Reads

How I treat early relapsing follicular lymphoma.

Blood 2019 Jan 30. Epub 2019 Jan 30.

Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, United States.

Follicular lymphoma (FL) is the most frequently occurring indolent non-Hodgkin lymphoma with generally favorable outcomes, but a variable clinical course. Recent studies have elucidated the consistent and reproducible frequency of early disease progression in FL, occurring in approximately 20% of patients. Relapse of FL within 24 months of chemoimmunotherapy (POD24) is now established as a robust marker of poor survival, leading to increased risk of death. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-08-822148DOI Listing
January 2019
1 Read

Primary central nervous system Hodgkin Lymphoma: A case discussion and a hypothesis on the etiology.

Avicenna J Med 2019 Jan-Mar;9(1):28-31

Hematogenix Laboratory Services, Tinley Park, IL, USA.

Hodgkin Lymphoma (HL) is a systemic disease with involvement of the cervical, supraclavicular, and mediastinal lymph nodes. It is commonly diagnosed in patients within the second and third decades of their lives. Diagnosis is usually made based on the distinct morphological and immunohistochemical characteristics, with the tissue biopsy being the cornerstone of workup. Read More

View Article

Download full-text PDF

Source
http://www.avicennajmed.com/preprintarticle.asp?id=240257
Publisher Site
http://dx.doi.org/10.4103/ajm.AJM_104_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6335883PMC
January 2019
5 Reads

Pre-treatment partial-volume-corrected TLG is the best predictor of overall survival in patients with relapsing/refractory non-hodgkin lymphoma following radioimmunotherapy.

Am J Nucl Med Mol Imaging 2018 20;8(6):407-414. Epub 2018 Dec 20.

Department of Radiology, Hospital of The University of Pennsylvania PA, USA.

The role of fluorodeoxyglucose-positron emission tomography (FDG-PET) has been well established in assessment of lymphoma, including non-Hodgkin lymphoma (NHL). The aim of this study was to compare changes and survival predictive values of various quantification parameters of FDG-PET/CT in patients with relapsing/refractory lymphoma before and after radioimmunotherapy (RIT). Data from 17 patients with relapsing/refractory NHL, treated with targeted RIT after chemotherapy/radiotherapy, were retrospectively collected. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6334213PMC
December 2018
28 Reads

Chronic fatigue and associated factors among long-term survivors of cancers in young adulthood.

Acta Oncol 2019 Jan 30:1-10. Epub 2019 Jan 30.

a National Advisory Unit on Late Effects after Cancer Treatment, Department of Oncology , Oslo University Hospital , Oslo , Norway.

Background: Chronic fatigue (CF) is scarcely explored among young adult cancer survivors (YACSs), and more knowledge is needed to develop targeted interventions for YACSs with CF. The present study aimed to investigate the prevalence of CF and associated factors in YACSs. Also, the change of fatigue with time was explored. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2018.1557344DOI Listing
January 2019
1 Read

Recent advances and future directions in mantle cell lymphoma research: report of the 2018 mantle cell lymphoma consortium workshop.

Leuk Lymphoma 2019 Jan 30:1-13. Epub 2019 Jan 30.

f GW Cancer Center, George Washington University , Washington , DC , USA.

Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma characterized by the t(11;14) chromosomal translocation. This translocation most often results in overexpression of cyclin D1. MCL is clinically heterogeneous, outcomes are generally poor, and no standard treatment has been established. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1571205DOI Listing
January 2019
1 Read

High-Performance Concurrent Chemo-Immuno-Radiotherapy for the Treatment of Hematologic Cancer through Selective High-Affinity Ligand Antibody Mimic-Functionalized Doxorubicin-Encapsulated Nanoparticles.

ACS Cent Sci 2019 Jan 26;5(1):122-144. Epub 2018 Dec 26.

Laboratory of Nano- and Translational Medicine, Carolina Center for Cancer Nanotechnology Excellence, Carolina Institute of Nanomedicine, and Department of Radiation Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.

Non-Hodgkin lymphoma is one of the most common types of cancer. Relapsed and refractory diseases are still common and remain significant challenges as the majority of these patients eventually succumb to the disease. Herein, we report a translatable concurrent chemo-immuno-radiotherapy (CIRT) strategy that utilizes fully synthetic antibody mimic Selective High-Affinity Ligand (SHAL)-functionalized doxorubicin-encapsulated nanoparticles (Dox NPs) for the treatment of human leukocyte antigen-D related (HLA-DR) antigen-overexpressed tumors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acscentsci.8b00746DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346391PMC
January 2019
1 Read

Disease-related factors affecting timely lymphoma diagnosis: a qualitative study exploring patient experiences.

Br J Gen Pract 2019 Feb 28;69(679):e134-e145. Epub 2019 Jan 28.

Epidemiology and Cancer Statistics Group, professor of epidemiology, Department of Health Sciences, University of York, York.

Background: Expediting cancer diagnosis is widely perceived as one way to improve patient outcomes. Evidence indicates that lymphoma diagnosis is often delayed, yet understanding of issues influencing this is incomplete.

Aim: To explore patients' and their relatives' perceptions of disease-related factors affecting time to diagnosis of Hodgkin and non-Hodgkin lymphoma. Read More

View Article

Download full-text PDF

Source
http://bjgp.org/lookup/doi/10.3399/bjgp19X701009
Publisher Site
http://dx.doi.org/10.3399/bjgp19X701009DOI Listing
February 2019
5 Reads

Is True Whole-body FDG-PET/CT required in paediatric lymphoma? An IAEA Multicentre Prospective Study.

J Nucl Med 2019 Jan 25. Epub 2019 Jan 25.

International Atomic Energy Agency, Austria.

Guidelines recommend true whole body (TWB) FDG-PET/CT scans from vertex to toes in paediatric lymphoma patients, although this suggestion has not been validated in large clinical trials. The objective of the study is to evaluate the incidence and clinical impact of lesions outside the "eyes to thighs" regular field of view (R-FOV) in FDG-PET/CT staging (sPET) and interim (iPET) scans in paediatric lymphoma patients. TWB sPET and iPET scans were prospectively performed in paediatric lymphoma patients (11 worldwide centres). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.118.222299DOI Listing
January 2019
3 Reads

The evaluation of mental disorders research reported in British and Irish newspapers between 2002 and 2013, and a comparison with the relative disease burdens and with research outputs in the two countries.

Health Policy 2019 Jan 15. Epub 2019 Jan 15.

King's College London, Division of Cancer Studies, Research Oncology, Guy's Hospital, King's College London, Great Maze Pond, London, SE1 6RT, UK; King's College London, Institute of Psychiatry, Psychology & Neuroscience, Centre for Implementation Science, De Crespigny Park, Denmark Hill, London, SE5 8AF, UK. Electronic address:

Mental disorders are a major contributor to the disease burden in Europe. We studied how research on them was communicated to British and Irish newspaper readers through an analysis of stories in the Daily Mail (DML) and The Guardian (GDN) in the UK and the Irish Times (IET) in Ireland, in 2002-13, and whether the coverage reflected the relative burdens of mental disorders, or the amount of research, in the two countries. The cited papers were identified through the newspapers' archive or the Factiva database, and their details and those of the research they cited from the Web of Science, with 1,128 stories in total. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.healthpol.2019.01.005DOI Listing
January 2019
1 Read

In brief: Brentuximab vedotin (Adcetris) for classical hodgkin's lymphoma.

Authors:

Med Lett Drugs Ther 2018 Nov 5;60(1559):e185. Epub 2018 Nov 5.

View Article

Download full-text PDF

Source
November 2018

Podocyte GSK3 is an evolutionarily conserved critical regulator of kidney function.

Nat Commun 2019 01 24;10(1):403. Epub 2019 Jan 24.

Bristol Renal, Dorothy Hodgkin Building, University of Bristol, Bristol, BS1 3NY, UK.

Albuminuria affects millions of people, and is an independent risk factor for kidney failure, cardiovascular morbidity and death. The key cell that prevents albuminuria is the terminally differentiated glomerular podocyte. Here we report the evolutionary importance of the enzyme Glycogen Synthase Kinase 3 (GSK3) for maintaining podocyte function in mice and the equivalent nephrocyte cell in Drosophila. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41467-018-08235-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6345761PMC
January 2019